Gastric Cancer EFS Improves With Perioperative Serplulimab
ASTRUM-006 found serplulimab plus perioperative SOX improved event-free survival in PD-L1-selected resectable gastric or gastroesophageal junction cancer, supporting biomarker-guided investigation.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.